Sorafenib with ASC‐J9(®) synergistically suppresses the HCC progression via altering the pSTAT3‐CCL2/Bcl2 signals

Sorafenib is currently used as a standard treatment to suppress the progression of hepatocellular carcinoma (HCC), especially in advanced stages. However, patients who receive Sorafenib treatment eventually develop resistance without clear mechanisms. There is a great need for better efficacy of Sor...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Junjie, Lin, Hui, Li, Gonghui, Sun, Yin, Shi, Liang, Ma, Wen‐Lung, Chen, Jiang, Cai, Xiujun, Chang, Chawnshang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Therapy and Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215679/
https://www.ncbi.nlm.nih.gov/pubmed/27668844
http://dx.doi.org/10.1002/ijc.30446

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215679/
https://www.ncbi.nlm.nih.gov/pubmed/27668844
http://dx.doi.org/10.1002/ijc.30446

Ejemplares similares